论文部分内容阅读
目的:检测三阴性乳腺癌CD133和HER-1表达状况并分析其与临床病理特征及预后相关关系。方法:用免疫组化方法检测67例三阴性乳腺癌的CD133、HER-1表达,并对其进行临床病理学分析。结果:三阴性乳腺癌中CD133、HER-1表达分别为43.3%(29/67)和53.7%(36/67)。CD133表达与肿瘤大小(P=0.025)、临床分期(P=0.003)、淋巴结转移有关(P=0.001);与年龄、组织学分级无关;CD133表达与患者总体生存率(Log-rank=9.346,P=0.002)和无瘤生存率(Log-rank=38.840,P=0.000 1)有关。HER-1表达与肿瘤大小(P=0.030)、临床分期(P=0.021)、淋巴结转移有关(P=0.002);与年龄、组织学分级无关;HER-1表达与患者总体生存率(Log-rank=7.998,P=0.005)和无瘤生存率(Log-rank=4.227,P=0.040)有关。结论:CD133、HER-1表达可能与三阴性乳腺癌的预后相关。
OBJECTIVE: To detect the expression of CD133 and HER-1 in triple negative breast cancer and analyze its relationship with clinicopathological features and prognosis. Methods: The expressions of CD133 and HER-1 in 67 cases of triple negative breast cancer were detected by immunohistochemistry and analyzed clinically and pathologically. Results: The expressions of CD133 and HER-1 in triple-negative breast cancer were 43.3% (29/67) and 53.7% (36/67), respectively. The expression of CD133 was correlated with tumor size (P = 0.025), clinical stage (P = 0.003) and lymph node metastasis (P = 0.001), but not with age and histological grade. P = 0.002) and tumor-free survival (Log-rank = 38.840, P = 0.000 1). The expression of HER-1 was correlated with tumor size (P = 0.030), clinical stage (P = 0.021) and lymph node metastasis (P = 0.002), but not with age and histological grade. The expression of HER- rank = 7.998, P = 0.005) and tumor-free survival (Log-rank = 4.227, P = 0.040). Conclusion: The expression of CD133 and HER-1 may be related to the prognosis of triple negative breast cancer.